Prothena Reports Third Quarter 2026 Financial Results and Business Highlights

Gene Kinney, President and Chief Executive Officer of Prothena

“During the quarter, Roche and Novo highlighted prasinezumab at Roche’s Pharma Day and coramitug at Novo’s Capital Markets Day, underscoring the potential of these Prothena-originated programs to address significant unmet needs in Parkinson’s disease and ATTR amyloidosis with cardiomyopathy, respectively. Novo also recently presented a post hoc analysis of the Phase 2 trial at the HFSA Annual Scientific Meeting showing that the inflammatory biomarker hsCRP decreased from baseline in patients treated with coramitug, while increasing in those receiving placebo. These findings complement the previously reported reduction in NT-proBNP and favorable functional and echocardiographic findings, further supporting coramitug’s potential as an amyloid-depleting treatment for ATTR-CM. Both programs are in Phase 3 clinical trials, PARAISO (prasinezumab) and CLEOPATTRA (coramitug), with primary completions expected in 2029”

Gene Kinney, President and Chief Executive Officer of Prothena

“Bristol Myers Squibb continues to conduct the Phase 2 TargetTau-1 trial evaluating moponetug in patients with early Alzheimer’s disease, with a data readout expected in the first half of 2027. Through our partnered programs, we have generated $650 million in upfront, milestone and equity payments and may potentially receive over $2.25 billion in additional milestone payments, plus potential royalties. Additionally, we are progressing our wholly-owned preclinical programs, including PRX012-TfR and TDP-43 CYTOPE. And finally, we continue to evaluate our proprietary CYTOPE(®) technology with industry partners through multiple research collaborations over the next 12 to 24 months.”